S
Sari H. Enschede
Researcher at AbbVie
Publications - 55
Citations - 8545
Sari H. Enschede is an academic researcher from AbbVie. The author has contributed to research in topics: Venetoclax & Chronic lymphocytic leukemia. The author has an hindex of 25, co-authored 55 publications receiving 7369 citations. Previous affiliations of Sari H. Enschede include Abbott Laboratories & Rush University Medical Center.
Papers
More filters
Journal ArticleDOI
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C.S. Huang,David C.S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Kylie D. Mason,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Deepak Sampath,John F. Seymour,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Michael D. Wendt,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +47 more
TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts,John F. Seymour,John F. Seymour,Jennifer R. Brown,William G. Wierda,Thomas J. Kipps,Seong Lin Khaw,Seong Lin Khaw,Dennis A. Carney,Dennis A. Carney,Simon He,Simon He,Simon He,David C.S. Huang,David C.S. Huang,David C.S. Huang,Hao Xiong,Yue Cui,Todd A. Busman,Evelyn McKeegan,Andrew Krivoshik,Sari H. Enschede,Rod A. Humerickhouse +22 more
TL;DR: BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.
Journal ArticleDOI
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson,Owen A. O'Connor,Myron S. Czuczman,Ann S. LaCasce,John F. Gerecitano,John P. Leonard,Anil Tulpule,Kieron Dunleavy,Hao Xiong,Yi-Lin Chiu,Yue Cui,Todd A. Busman,Steven W. Elmore,Saul H. Rosenberg,Andrew Krivoshik,Sari H. Enschede,Rod A. Humerickhouse +16 more
TL;DR: Navitoclax showed a pharmacodynamic effect on circulating platelets and T cells and has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of Bcl-XL and BCL-2, respectively.
Journal ArticleDOI
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Steven Coutre,John F. Seymour,Talha Munir,Soham D. Puvvada,Clemens M. Wendtner,Andrew W. Roberts,Wojciech Jurczak,Stephen P. Mulligan,Sebastian Böttcher,Mehrdad Mobasher,Ming Zhu,Monali Desai,Brenda Chyla,Maria Verdugo,Sari H. Enschede,Elisa Cerri,Rod A. Humerickhouse,Gary Gordon,Michael Hallek,William G. Wierda +22 more
TL;DR: Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population.